Related references
Note: Only part of the references are listed.Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1
Sergey M. Deyev et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2020)
Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers
Charles Dahlsson Leitao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2
Anzhelika Vorobyeva et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
C. Willemien Menke-van der Houven van Oordt et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111
Sara S. Rinne et al.
SCIENTIFIC REPORTS (2019)
HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model
John S. Schardt et al.
AAPS JOURNAL (2019)
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Lecia Sequist et al.
ONCOLOGIST (2019)
Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging
Anzhelika Vorobyeva et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake
Maria Rosestedt et al.
SCIENTIFIC REPORTS (2019)
Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules
Sara S. Rinne et al.
SCIENTIFIC REPORTS (2019)
Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties
Sergey Deyev et al.
MOLECULAR PHARMACEUTICS (2019)
An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
Kimio Yonesaka et al.
ONCOGENE (2019)
Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label
Sarah Lindbo et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide
Benjamin M. Larimer et al.
MOLECULAR IMAGING AND BIOLOGY (2018)
Clinical development of HER3-targeting monoclonal antibodies: Perils and progress
Wolfgang Jacob et al.
CANCER TREATMENT REVIEWS (2018)
Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology
Ahmet Krasniqi et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab
Anna Orlova et al.
MOLECULAR PHARMACEUTICS (2018)
Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications
Ruisi Fu et al.
CHEMMEDCHEM (2018)
HER3 signaling and targeted therapy in cancer
Rosalin Mishra et al.
ONCOLOGY REVIEWS (2018)
Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer
Kelly E. Henry et al.
PET CLINICS (2018)
Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of 89Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging
Frank J. Warnders et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment
Martin Pool et al.
MABS (2017)
Affibody Molecules in Biotechnological and Medical Applications
Stefan Stahl et al.
TRENDS IN BIOTECHNOLOGY (2017)
The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule
Javad Garousi et al.
SCIENTIFIC REPORTS (2017)
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
Birgit Schoeberl et al.
NPJ SYSTEMS BIOLOGY AND APPLICATIONS (2017)
89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
Frederike Bensch et al.
CLINICAL CANCER RESEARCH (2017)
Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors
A. Craig Lockhart et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
Efficient [18F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors
Chiara Da Pieve et al.
BIOCONJUGATE CHEMISTRY (2016)
Novel chemoselective F-18-radiolabeling of thiol-containing biomolecules under mild aqueous conditions
Aristeidis Chiotellis et al.
CHEMICAL COMMUNICATIONS (2016)
Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance
Eric Wehrenberg-Klee et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Jens Sorensen et al.
THERANOSTICS (2016)
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model
Michael D. Curley et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Affibody-mediated PET imaging of HER3 expression in malignant tumours
Maria Rosestedt et al.
SCIENTIFIC REPORTS (2015)
Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
Joanna Strand et al.
CHEMISTRYOPEN (2015)
Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome
Jill M. Siegfried et al.
NEOPLASIA (2015)
Incorporation of a Triglutamyl Spacer Improves the Biodistribution of Synthetic Affibody Molecules Radiofluorinated at the N-Terminus via Oxime Formation with 18F-4-Fluorobenzaldehyde
Daniel Rosik et al.
BIOCONJUGATE CHEMISTRY (2014)
Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)3-HEHEHE-ZHER3:08699 affibody molecule
Anna Orlova et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody 89Zr-RG7116
Anton G. T. Terwisscha van Scheltinga et al.
MABS (2014)
HER3, serious partner in crime Therapeutic approaches and potential biomarkers for effect of HER3-targeting
Arjan Kol et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Methods for Radiolabelling of Monoclonal Antibodies
Vladimir Tolmachev et al.
HUMAN MONOCLONAL ANTIBODIES: METHODS AND PROTOCOLS (2014)
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
Allan Lipton et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Correction: Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification
Magdalena Malm et al.
PLoS One (2013)
Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition
Vladimir Tolmachev et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
Anindita Chakrabarty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody
Jennie Malmberg et al.
NUCLEAR MEDICINE AND BIOLOGY (2011)
ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma
J. Spencer Liles et al.
CANCER BIOLOGY & THERAPY (2010)
Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount
Vladimir Tolmachev et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
ErbB receptors and signaling pathways in cancer
Nancy E. Hynes et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules
Vladimir Tolmachev et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Slow internalization of anti-HER2 synthetic Affibody monomer 111In-DOTA-ZHER2:342-pep2:: Implications for development of labeled tracers
Helena Wallberg et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2008)
High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer
Mikiko Hayashi et al.
CLINICAL CANCER RESEARCH (2008)
[18F]FBEM-ZHER2:342 -: Affibody molecule -: a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography
Gabriela Kramer-Marek et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
ErbB-3 predicts survival in ovarian cancer
Berno Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Expression and nuclear localization of ErbB3 in prostate cancer
IH Koumakpayi et al.
CLINICAL CANCER RESEARCH (2006)
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics
AC Steffen et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
